Brief: ARS Pharmaceuticals CHMP Opinion On Neffy Marketing Authorization Application Expected In Q2 2024
30/04/2024 14:26
April 30 (Reuters) - CSL Ltd CSL.AX :
* ARS PHARMACEUTICALS SUBMITS RESPONSE FOR NEFFY®
(EPINEPHRINE
NASAL SPRAY) MARKETING AUTHORIZATION APPLICATION TO EMA’S CHMP
AND ENTERS LICENSE AGREEMENT WITH CSL SEQIRUS FOR
COMMERCIALIZATION OF NEFFY IN AUSTRALIA AND NEW ZEALAND
* ARS PHARMACEUTICALS INC: CHMP OPINION ON NEFFY MARKETING
AUTHORIZATION APPLICATION ANTICIPATED IN Q2 OF 2024
Source text for Eikon: ID:nGNX64VQpp
Further company coverage: CSL.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ARS Pharmaceuticals
See all newsARS Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
ARS Pharmaceuticals Q2 neffy revenue rises as epinephrine market share doubles
U.S. STOCKS ON THE MOVE-Bumble, Tempus AI, TD Synnex
U.S. STOCKS ON THE MOVE-Bio-Techne, IBM, Apple
ARS Pharma tumbles as allergy nasal spray faces insurance coverage hurdle